Why the study?
Do AT1 receptor antagonists provide similar or better renoprotection compared to ACE inhibitors in diabetic nephropathy?
Population
Diabetic patients with microalbuminuria or overt proteinuria (and animal models of diabetic kidney disease)
Comparison
AT1 receptor antagonists vs ACE inhibitors
Design
Review
Authors
Loading...
Animal data support testing AT1 antagonists in diabetic nephropathy trials; leaves open clinical equivalence to ACE inhibitors.
Do AT1 receptor antagonists provide similar or better renoprotection compared to ACE inhibitors in diabetic nephropathy?
AT1 receptor antagonists represent a promising, better-tolerated alternative to ACE inhibitors for diabetic nephropathy, with comparable renoprotective effects demonstrated in animal models.
Mogyorósi et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: